|  | ECLS (N=275) | ECMELLA (N=136) | Overall (N=411) |
| --- | --- | --- | --- |
| **Age (years)** |  |  |  |
| Mean (SD) | 62.8 (13.8) | 60.0 (12.4) | 61.9 (13.4) |
| Median [Min, Max] | 65.0 [18.0, 87.0] | 61.0 [21.0, 83.0] | 64.0 [18.0, 87.0] |
| Missing | 0 (0%) | 1 (0.7%) | 1 (0.2%) |
| **Sex** |  |  |  |
| female | 81 (29.5%) | 29 (21.3%) | 110 (26.8%) |
| male | 194 (70.5%) | 107 (78.7%) | 301 (73.2%) |
| **BMI** |  |  |  |
| Mean (SD) | 28.0 (5.92) | 27.5 (6.05) | 27.8 (5.97) |
| Median [Min, Max] | 27.4 [15.8, 49.6] | 26.1 [15.9, 51.5] | 26.8 [15.8, 51.5] |
| Missing | 29 (10.5%) | 4 (2.9%) | 33 (8.0%) |
| **Diabetes (Type II)** |  |  |  |
| Yes | 75 (27.3%) | 56 (41.2%) | 131 (31.9%) |
| No | 190 (69.1%) | 71 (52.2%) | 261 (63.5%) |
| Missing | 10 (3.6%) | 9 (6.6%) | 19 (4.6%) |
| **Chronic kidney disease** |  |  |  |
| Yes | 71 (25.8%) | 35 (25.7%) | 106 (25.8%) |
| No | 192 (69.8%) | 91 (66.9%) | 283 (68.9%) |
| Missing | 12 (4.4%) | 10 (7.4%) | 22 (5.4%) |
| **Chronic kidney disease (stage)ᵃ** |  |  |  |
| Mean (SD) | 3.56 (1.17) | 3.29 (1.27) | 3.48 (1.20) |
| Median [Min, Max] | 3.00 [2.00, 6.00] | 3.00 [2.00, 6.00] | 3.00 [2.00, 6.00] |
| Missing | 213 (77.5%) | 108 (79.4%) | 321 (78.1%) |
| **Chronic obstructive pulmonary disease** |  |  |  |
| Yes | 31 (11.3%) | 16 (11.8%) | 47 (11.4%) |
| No | 234 (85.1%) | 101 (74.3%) | 335 (81.5%) |
| Missing | 10 (3.6%) | 19 (14.0%) | 29 (7.1%) |
| **Chronic obstructive pulmonary disease (stage)** |  |  |  |
| Mean (SD) | 3.47 (1.57) | 3.88 (1.26) | 3.61 (1.47) |
| Median [Min, Max] | 3.50 [1.00, 5.00] | 4.50 [2.00, 5.00] | 4.00 [1.00, 5.00] |
| Missing | 245 (89.1%) | 120 (88.2%) | 365 (88.8%) |
| **Lactate (mg/dL)** |  |  |  |
| Mean (SD) | 74.8 (54.4) | 65.4 (43.7) | 71.8 (51.4) |
| Median [Min, Max] | 62.0 [4.00, 229] | 57.0 [4.00, 200] | 60.0 [4.00, 229] |
| Missing | 40 (14.5%) | 29 (21.3%) | 69 (16.8%) |
| **Median pH** |  |  |  |
| Mean (SD) | 7.44 (0.0603) | 7.43 (0.0723) | 7.44 (0.0652) |
| Median [Min, Max] | 7.44 [7.25, 7.64] | 7.44 [7.04, 7.54] | 7.44 [7.04, 7.64] |
| Missing | 62 (22.5%) | 9 (6.6%) | 71 (17.3%) |
| **Vasoactive-inotropic score (VIS)ᵇ** |  |  |  |
| Mean (SD) | 38.0 (29.6) | 41.5 (29.5) | 39.3 (29.5) |
| Median [Min, Max] | 28.5 [1.00, 100] | 35.5 [2.00, 100] | 31.5 [1.00, 100] |
| Missing | 149 (54.2%) | 64 (47.1%) | 213 (51.8%) |
| **RRT required (prior to tMCS)** |  |  |  |
| Yes | 35 (12.7%) | 11 (8.1%) | 46 (11.2%) |
| No | 237 (86.2%) | 122 (89.7%) | 359 (87.3%) |
| Missing | 3 (1.1%) | 3 (2.2%) | 6 (1.5%) |
| **Median creatinine (mg/dL)** |  |  |  |
| Mean (SD) | 1.91 (1.06) | 1.72 (0.931) | 1.84 (1.02) |
| Median [Min, Max] | 1.70 [0.500, 6.00] | 1.50 [0.400, 6.00] | 1.63 [0.400, 6.00] |
| Missing | 60 (21.8%) | 11 (8.1%) | 71 (17.3%) |
| **Etiology of cardiogenic shock** |  |  |  |
| No shock | 133 (48.4%) | 25 (18.4%) | 158 (38.4%) |
| AHF | 48 (17.5%) | 55 (40.4%) | 103 (25.1%) |
| AMICS | 43 (15.6%) | 44 (32.4%) | 87 (21.2%) |
| PCCS | 4 (1.5%) | 2 (1.5%) | 6 (1.5%) |
| Other | 47 (17.1%) | 10 (7.4%) | 57 (13.9%) |
| **Previous cardiac arrest** |  |  |  |
| Yes | 91 (33.1%) | 56 (41.2%) | 147 (35.8%) |
| No | 184 (66.9%) | 80 (58.8%) | 264 (64.2%) |
| **eCPR** |  |  |  |
| Yes | 13 (4.7%) | 5 (3.7%) | 18 (4.4%) |
| No | 262 (95.3%) | 131 (96.3%) | 393 (95.6%) |
| **Nephrotoxic drugsᶜ** |  |  |  |
| Yes | 71 (25.8%) | 58 (42.6%) | 129 (31.4%) |
| No | 148 (53.8%) | 69 (50.7%) | 217 (52.8%) |
| Missing | 56 (20.4%) | 9 (6.6%) | 65 (15.8%) |
| ᵃ Stage 3a and 3b were coded as 3 and 4, respectively. The remaining stages were increased by one value.<br>ᵇ VIS, a weighted sum of vasopressor and inotropic medications, quantifies the amount of pharmacological cardiovascular support in patients on tMCS.<br>ᶜ Vancomycin (IV), gentamycin, or tobramycin | | | |